JOY SCARBOROUGH: Open Payments
NPI 1982740957 · DUBLIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$250 in 12 payments from 8 companies in 2025. Trend: 2023 $203 · 2024 $142 · 2025 $250
Food & beverage: $250
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 4 | $80 |
| Biogen, Inc. | 2 | $41 |
| Lilly USA, LLC | 1 | $24 |
| PFIZER INC. | 1 | $24 |
| Novo Nordisk Inc | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| ABBVIE INC. | 1 | $21 |
| Exeltis, USA Inc. | 1 | $16 |
Products named: GEMTESA, ZURZUVAE, ZEPBOUND, ABRYSVO, Wegovy, Veozah, LO LOESTRIN FE, MYFEMBREE.
Industry payments across GA — which companies pay providers there.
